359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
Saved in:
| Title: | 359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study |
|---|---|
| Authors: | Nakayama, T.1 (AUTHOR), Nagai, S.E.2 (AUTHOR), Hattori, M.3 (AUTHOR), Yoshinami, T.4 (AUTHOR), Masuda, H.5 (AUTHOR), Okamura, T.6 (AUTHOR), Watanabe, K-I.7 (AUTHOR), Tsuneizumi, M.8 (AUTHOR), Takabatake, D.9 (AUTHOR), Harao, M.10 (AUTHOR), Yasojima, H.11 (AUTHOR), Oshiro, C.12 (AUTHOR), Iwase, M.13 (AUTHOR), Yamaguchi, M.14 (AUTHOR), Sangai, T.15 (AUTHOR), Sasada, S.16 (AUTHOR), Ishida, T.17 (AUTHOR), Futamura, M.18 (AUTHOR), Kosaka, N.19 (AUTHOR), Masuda, N.20 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS368-S368. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.307 |
